Skip to content
Biotron Limited
  • Home
  • About Us
    • Board of Directors
    • Management Team
  • Technology
    • Clinical programs
    • Non-clinical programs
    • Intellectual property
  • News/Resources
    • Newsletters
    • In the news
    • Scientific Presentations
    • Scientific Publications
  • Investor Centre
    • ASX Announcements
    • Financial Reports
      • Annual
      • Half-year
      • Quarterly
    • Corporate Directory
    • Shareholder services
    • Rights Issue
    • Top 40 Shareholders
    • Top 40 Option Holders
    • Corporate Governance
    • Corporate Presentations
  • Contacts

2016

Half-year report 31 December 2015

26 February 2016 by Karen Mobbs

Half-year report 31 December 2015

Categories 2016, ASX Announcements, Half-year reports

Data Indicates BIT225 May Have a Broader Role in Limiting HIV-1 Infection

18 February 2016 by Justine Bednorz

Data Indicates BIT225 May Have a Broader Role in Limiting HIV-1 Infection

Categories 2016, ASX Announcements

Biotron Anti-Viral Compounds to be Tested in USA for Activity Against Zika Virus

17 February 201616 February 2016 by Justine Bednorz

Biotron Anti-Viral Compounds to be Tested in USA for Activity Against Zika Virus

Categories 2016, ASX Announcements

Appendix 4C

17 February 201615 January 2016 by Justine Bednorz

Appendix 4C

Categories 2016, ASX Announcements

New Issue Announcement – Appendix 3B

17 February 201615 January 2016 by Justine Bednorz

New Issue Announcement – Appendix 3B

Categories 2016, ASX Announcements

Biotron Limited Presents at Biotech Showcase 2016

12 January 2016 by Audrey Thomson

Biotron Limited Presents at Biotech Showcase 2016

Categories 2016, ASX Announcements
Newer posts
← Previous Page1 Page2 Page3
© Biotron Limited 2016       ABN 60 086 399 144        Site updated 6 June 2025        Legal Notices and Privacy
Cleantalk Pixel